The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Investigating the Movement of Intravitreal Human Serum Albumin Nanoparticles in the Vitreous and Retina
Abstract
Purpose To investigate the movement of intravitreally injected human serum albumin nanoparticles (HSA-NP) with respect to nanoparticle surface charge and retinal injury.Methods HSA-NPs were developed by a desolvation technique. HSA-NPs were cationized by covalent coupling of hexamethylenediamine on the particle surface. Either anionic or cationic HSA-NPs were injected to determine the effect of surface charge on intravitreal nanoparticle movement. HSA-NPs were injected intravitreally into both normal and laser photocoagulated eyes to examine the effect of the integrity of retinal tissue on the retinal penetration. The retinal penetration of fluorescence labeled anionic HSA-NPs was investigated by confocal microscopy.Results Anionic particles (-33.3+/-6.1 mV) more easily diffused through the 3-dimensional vitreal network of collagen fibrils than did their cationic counterparts (11.7+/-7.2 mV). In the laser photocoagulated retina, more HSA-NPs were detected in the choroidal space, compared to the normal retina. The immunohistochemical studies indicated that HSA-NPs were taken up into Müller cells.Conclusions The movement of intravitreal nanoparticles depended on both nanoparticles surface charge and retinal injury. The Müller cells might play an important role in the retinal penetration of nanoparticles. The anionic HSA-NP is a promising drug or gene delivery carrier to the sub-retinal space and RPE.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strategies such as PEGylation [271], charge modification [272], and coating with hyaluronate or chloroquine [273,274] have been shown to improve retinal transduction in animal models when administered intravitreally.”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [272]
Citations
Cites
(1984) · PubMed · Cited by 1,200
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107
Nanoparticulate systems for brain delivery of drugs
Kreuter, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.015 · Cited by 965
Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema
Jonas, J. B. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.1.57 · Cited by 567
Nanotechnology in ocular drug delivery
Sahoo, S. K., Dilnawaz, F., & Krishnakumar, S. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.021 · Cited by 554
Nanotechnology in Ocular Drug Delivery
Patel, D. H., Pathak, D., & Giradkar, P. (2021) · Springer eBooks · doi:10.1007/978-981-33-4497-6_18 · Cited by 362
Bourges, J., Gautier, S., Delié, F., Bejjani, R. A., Jeanny, J., Gurny, R., BenEzra, D., & Béhar‐Cohen, F. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-1068 · Cited by 357
Ruponen, M., Ylä‐Herttuala, S., & Urtti, A. O. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(98)00199-0 · Cited by 352
Drug delivery for posterior segment eye disease.
Geroski, D. H., & Edelhauser, H. F. (2000) · PubMed · Cited by 341
Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery
Lü, W., Zhang, Y., Tan, Y., Hu, K., Jiang, X., & Fu, S. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.027 · Cited by 317
Nanomedicines for overcoming biological barriers
Alonso, M. J. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.01.007 · Cited by 312
Factor VIII related antigen as an endothelial cell marker in benign and malignant diseases
Sehested, M., & HOU-JENSEN, K. (1981) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00437598 · Cited by 259
Drug delivery to the retina: challenges and opportunities
Duvvuri, S., Majumdar, S., & Mitra, A. K. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.1.45 · Cited by 238
Secondary Chronic Open-Angle Glaucoma After Intravitreal Triamcinolone Acetonide
Jonas, J. B. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.5.729 · Cited by 218
Vitreous: A Barrier to Nonviral Ocular Gene Therapy
Peeters, L., Sanders, N. N., Braeckmans, K., Boussery, K., Van de Voorde, J., De Smedt, S. C., & Demeester, J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0165 · Cited by 189 · cited 3×
“These glycosaminoglycans are known to interact with polymeric and liposomal DNA complexes (20, 21 ).”
InfluentialKamei, M., Misono, K., & Lewis, H. (1999) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(99)00239-1 · Cited by 169
Marano, R. J., Tóth, I., Wimmer, N., Brankov, M., & Rakoczy, P. E. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302579 · Cited by 164
Nanoparticles for gene delivery to retinal pigment epithelial cells.
Bejjani, R. A., BenEzra, D., Cohen, H., Rieger, J., Andrieu‐Soler, C., Jeanny, J., Gollomb, G., & Béhar‐Cohen, F. (2005) · PubMed · Cited by 163
Desolvation process and surface characteristics of HSA-nanoparticles
Weber, C., Kreuter, J., & Langer, K. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00420-2 · Cited by 158
Effect of Particle Size of Polymeric Nanospheres on Intravitreal Kinetics
Sakurai, E., Ozeki, H., Kunou, N., & Ogura, Y. (2000) · Ophthalmic Research · doi:10.1159/000055638 · Cited by 156
Human Retinal Molecular Weight Exclusion Limit and Estimate of Species Variation
Jackson, T. L., Antcliff, R. J., Hillenkamp, J., & Marshall, J. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-1027 · Cited by 145
Zonulae adherentes pore size in the external limiting membrane of the rabbit retina.
Milam, A. H., Saari, J. C., Klock, I. B., & Garwin, G. G. (1985) · PubMed · Cited by 142
Vitreous Is a Barrier in Nonviral Gene Transfer by Cationic Lipids and Polymers
Pitkänen, L., Ruponen, M., Nieminen, J., & Urtti, A. (2003) · Pharmaceutical Research · doi:10.1023/a:1023238530504 · Cited by 134
Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene.
Mo, Y., Barnett, M. E., Takemoto, D. J., Davidson, H. J., & Kompella, U. B. (2007) · PubMed Central · Cited by 133
Albumin Nanoparticles for the Intravitreal Delivery of Anticytomegaloviral Drugs
Irache, J. M., Merodio, M., Arnedo, A., Camapanero, M., Mirshahi, M., & Espuelas, S. (2005) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557053175335 · Cited by 131
de Kozak, Y., Andrieux, K., Villarroya, H., Klein, C., Thillaye‐Goldenberg, B., Naud, M., Garcia, E., & Couvreur, P. (2004) · European Journal of Immunology · doi:10.1002/eji.200425022 · Cited by 130
Chen, H., & Weber, A. J. (2002) · Glia · doi:10.1002/glia.10061 · Cited by 105
Distribution of glycoconjugates in the human retinal internal limiting membrane.
Russell, S. R., Shepherd, J. D., & Hageman, G. S. (1991) · PubMed · Cited by 84
Lim, J. I., Wolitz, R. A., Dowling, A., Bloom, H. R., Irvine, A. R., & Schwartz, D. M. (1999) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(98)00443-7 · Cited by 76
Structure and composition of the inner limiting membrane of the retina
Heegaard, S., Jensen, O. A., & Prause, J. U. (1986) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/bf02150029 · Cited by 66
Fischer, D., Bieber, T., Brüsselbach, S., Elsässer, H., & Kissel, T. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00765-7 · Cited by 52
Fukuchi, T., Takahashi, K. A., & Shou, K. (2001) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s004170000205 · Cited by 48
VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
Normand, N., Valamanesh, F., Savoldelli, M., Mascarelli, F., BenEzra, D., Courtois, Y., & Béhar‐Cohen, F. (2005) · PubMed · Cited by 41
Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis
Shane, T. S., & Martin, D. F. (2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(03)00333-7 · Cited by 40
Los, L. I., van Luyn, M. J. A., & Nieuwenhuis, P. (1999) · Experimental Eye Research · doi:10.1006/exer.1999.0708 · Cited by 29
Potential of Albumin Nanoparticles as Carriers for Interferon Gamma
Segura, S., Espuelas, S., Renedo, M. J., & Irache, J. M. (2005) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-52063 · Cited by 27
Chai, L., & Morris, J. E. (1994) · Current Eye Research · doi:10.3109/02713689408999903 · Cited by 20
Nishihara, H. (1991) · PubMed · Cited by 20
Cited by
Sorted by citations
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,526
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Ocular drug delivery systems: An overview
Patel, A. (2013) · World Journal of Pharmacology · doi:10.5497/wjp.v2.i2.47 · Cited by 894
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Jo, D. H., Kim, J. H., Lee, T. G., & Kim, J. H. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.04.015 · Cited by 445
Metadata
- Authors
- Kim, H., Robinson, S. B., & Csaky, K. G.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- Corresponding author
- Kim, Hyuncheol
- Venue
- Pharmaceutical Research
- Published
- 2008-10-29
- Volume
- 26
- Issue
- 2
- Pages
- 329-337
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2026741029
- Cited by
- 174
- References
- 38
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 9 · 2023: 12 · 2022: 13 · 2021: 15 · 2020: 9 · 2019: 14 · 2018: 15 · 2017: 15 · 2016: 9 · 2015: 14 · 2014: 10 · 2013: 9 · 2012: 5
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- human serum albumin nanoparticles, intravitreal injection, vitreous humor, surface charge, cationic nanoparticles, anionic nanoparticles, laser photocoagulation, retinal damage, Müller cells, choroid, retinal pigment epithelium
- MeSH terms
- Animals, Choroid, Diamines, Diffusion, Drug Carriers, Fluorescent Dyes, Humans, Immunohistochemistry, Particle Size, Retina, Serum Albumin, Surface Properties, Vitreous Body, Bruch Membrane, Microscopy, Confocal, Rats, Laser Therapy, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review